| __timestamp | Amphastar Pharmaceuticals, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 7050000 |
| Thursday, January 1, 2015 | 37065000 | 8413000 |
| Friday, January 1, 2016 | 41199000 | 12038000 |
| Sunday, January 1, 2017 | 43415000 | 17900000 |
| Monday, January 1, 2018 | 57564000 | 15765000 |
| Tuesday, January 1, 2019 | 68853000 | 11140000 |
| Wednesday, January 1, 2020 | 67229000 | 11715000 |
| Friday, January 1, 2021 | 60932000 | 17344000 |
| Saturday, January 1, 2022 | 74771000 | 22829000 |
| Sunday, January 1, 2023 | 73741000 | 12665000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Amphastar Pharmaceuticals, Inc. has consistently outpaced MiMedx Group, Inc. in R&D investment. From 2014 to 2023, Amphastar's R&D expenses grew by approximately 160%, peaking in 2022 with a 74.8 million USD investment. In contrast, MiMedx's R&D spending increased by about 82% over the same period, reaching its highest in 2022 with 22.8 million USD.
This trend highlights Amphastar's strategic focus on innovation, investing nearly three times more than MiMedx on average. Such financial commitment is crucial for developing new therapies and maintaining a competitive edge. As the pharmaceutical landscape continues to shift, these investments will likely play a pivotal role in shaping the future of healthcare.
Merck & Co., Inc. or MiMedx Group, Inc.: Who Invests More in Innovation?
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs MiMedx Group, Inc.
Research and Development: Comparing Key Metrics for Summit Therapeutics Inc. and MiMedx Group, Inc.
R&D Spending Showdown: Pharming Group N.V. vs Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Verona Pharma plc vs Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: ADMA Biologics, Inc. vs Amphastar Pharmaceuticals, Inc.
R&D Insights: How ADMA Biologics, Inc. and MiMedx Group, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
R&D Spending Showdown: Soleno Therapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Iovance Biotherapeutics, Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?